Concise review: Role of DEK in stem/progenitor cell biology

Stem Cells

Volumn 31, Issue 8, 2013, Pages 1447-1453

  Broxmeyer, Hal E ^a   Mor Vaknin, Nirit ^b   Kappes, Ferdinand ^c   Legendre, Maureen ^b   Saha, Anjan K ^b   Ou, Xuan ^a   O'leary, Heather ^a   Capitano, Maegan ^a   Cooper, Scott ^a   Markovitz, David M ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Chromatin; DEK; Dipeptidylpeptidase IV; Hematopoietic progenitor cells; Hematopoietic stem cells; Receptors

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; DIPEPTIDYL PEPTIDASE IV; NUCLEAR PROTEIN; PHOSPHOPROTEIN; PROTEIN DEK; UNCLASSIFIED DRUG;

BONE MARROW CELL; BONE MARROW SUPPRESSION; CELL ACTIVITY; CELL DIFFERENTIATION; CELL MATURATION; CELL POPULATION; CELL PROLIFERATION; CYTOLOGY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; STEM CELL;

CHROMATIN; DEK; DIPEPTIDYLPEPTIDASE IV; HEMATOPOIETIC PROGENITOR CELLS; HEMATOPOIETIC STEM CELLS; RECEPTORS;

ANIMALS; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA-BINDING PROTEINS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; ONCOGENE PROTEINS;

EID: 84883379108     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1443     Document Type: Review

References (73)

1. Broxmeyer HE, Smith FO. Cord blood hematopoietic cell transplantation. In: Applelbaum FR, Forman SJ, Negrin RS et al. eds. Thomas' Hematopoietic Cell Transplantation. 4th ed. West Sussex, UK: Wiley-Blackwell, 2009:559-576.
2. Shaheen M, Broxmeyer, HE. The humoral regulation of hematopoiesis. In: Hoffman R, Benz EJ Jr, Shattil SJ et al, eds. Hematology: Basic Principles and Practice. Philadelphia, PA: Elsevier Churchill Livingston, 2009:253-275.
3. von Lindern M, Fornerod M, van Baal S et al. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol Cell Biol 1992;12: 1687-1697.
4. Broxmeyer HE, Kappes F, Mor-Vaknin N et al. DEK regulates hematopoietic stem engraftment and progenitor cell proliferation. Stem Cells Dev 2012;21:1449-1454.
5. Koleva RI, Ficarro SB, Radomska HS et al. C/EBPa and DEK coordinately regulate myeloid differentiation. Blood 2012;119:4878-4888.
6. Broxmeyer HE, Hoggatt J, O'Leary HA et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nat Med 2012;18:1786-1796.
7. Christopherson KW 2nd, Hangoc G, Broxmeyer HE. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cellderived factor-1 alpha-mediated chemotaxis of human cord blood CD341 progenitor cells. J Immunol 2002;169:7000-7008.
8. O'Leary H, Ou X, Broxmeyer HE. The role of dipeptidylpeptidase 4 in hematopoiesis and transplantation. Curr Opin Hematopoiesis 2013; 20:314-319.
9. Ou X, O'Leary H, Broxmeyer HE. Implications of DPP4 modifications of proteins that regulate stem/progenitors and more mature cell types. Blood. 2013 (in press).
10. Kappes F, Waldmann T, Mathew V et al. The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity. Genes Dev 2011; 25:673-678.
11. Saha AK, Kappes F, Mundade A. Intercellular trafficking of the nuclear oncoprotein DEK. Proc Natl Acad Sci USA. 2013 (in press).
12. Kappes F, Damoc C, Knippers R et al. Phosphorylation by protein kinase CK2 changes the DNA binding properties of the human chromatin protein DEK. Mol Cell Biol 2004;24:6011-6020.
13. Faulkner NE, Hilfinger JM, Markovitz DM. Protein phosphatase 2A activates the HIV-2 promoter through enhancer elements that include the pets site. J Biol Chem 2001;276:25804-25812.
14. Cleary J, Sitwala KV, Khodadoust MS et al. p300/CBP-associated factor drives DEK into interchromatin granule clusters. J Biol Chem 2005;280:31760-31767.
15. Mor-Vaknin N, Kappes F, Dick AE et al. DEK in the synovium of patients with juvenile idiopathic arthritis. Arthritis Rheumat 2011;63: 556-567.
16. Kappes F, Fahrer J, Khodadoust MS et al. DEK is a poly(ADPRibose) acceptor in apoptosis and mediates resistance to genotoxic stress. Mol Cell Biol 2008;28:3245-3257.
17. Fahrer J, Popp O, Malanga M et al. High affinity interaction of poly (ADP-ribose) and the human DEK oncoprotein depends upon chain length. Biochemistry 2010;49:7119-7130.
18. Sitwala KV, Adams K, Markovitz DM. YY1 and NF-Y binding sites regulate the transcriptional activity of the dek and dek-can promoter. Oncogene 2002;21:8862-8870.
19. Carro MS, Spiga FM, Quarto M et al. DEK expression is controlled by E2F and degraded in diverse tumor types. Cell Cycle 2006;5:1202-1207.
20. Privette Vinnedge LM, Ho S-K et al. The DEK oncogene is a target of steroid hormone receptor signaling in breast cancer. Plos One 2012; 7:e46985.
21. Babaei-Jadidi R, Li N, Saadeddin A. FBXW7 influences murine intestinal homeostasis and cancer, targeting, Notch, Jun, and Dek for degradation. J Exp Med 2011;208:295-312.
22. Cheung TH, Quach NL, Charville GW et al. Maintenance of muscle stem-cell quiescence by microRNA-489. Nature 2012;482:524-530.
23. Sammons M, Wan SS, Vogel NL et al. Negative regulation of the RelA/p65 transactivation function by the product of the DEK protooncogene. J Biol Chem 2006;281:26802-26812.
24. Gamble MJ, Fisher RP. SET and PARP1 remove DEK from chromatin to permit access by the transcription machinery. Nat Struct Mol Biol 2007;14:548-555.
25. Kappes F, Scholten I, Richter N et al. Functional domains of the ubiuitous chromatin protein DEK. Mol Cell Biol 2004;24:6000-6010.
26. Sawatsubashi S, Murata T, Lim J et al. A histone chaperone, DEK, transcriptionally coactivates a nuclear receptor. Genes Dev 2010;24: 159-170.
27. Shaheen M, Broxmeyer HE. Principles of cytokine signaling. In: Hoffman R, Benz EJ Jr, Silberstein LE et al., eds. Hematology: Basic Principles and Practice. 6th ed, chapter 14. Philadelphia, PA: Elsevier Churchill Livingston, 2012:136-146.
28. Privette Vinnedge LM, McClaine R, Wagh PK et al. The human DEK oncogene stimulates b-catenin signaling, invasion and mammosphere formation in breast cancer. Oncogene 2011;30:2741-2752.
29. Wise-Draper TM, Allen HV, Jones EE et al. Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. Mol Cell Biol 2006;26:7506-7519.
30. Wise-Draper TM, Allen HV, Thobe MN et al. The human DEK protooncogene is a senescence inhibitor and an upregulated target of highrisk human papillomavirus E7. J Virol 2005;79:14309-14317.
31. Wise-Draper TM, Mintz-Cole RA, Morris TA et al. Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo. Cancer Res 2009;69:1792-1799.
32. Wise-Draper TM, Morreale RJ, Morris TA et al. DEK proto-oncogene expression interferes with the normal epithelial differentiation program. Amer J Pathol 2009;174:71-81.
33. Khodadoust MS, Verhaegen M, Kappes F et al. Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res 2009;69:6405-6413.
34. Riveiro-Falkenbach E, Soengas MS. Control of tumorigenesis and chemoresistance by the DEK oncogene. Clin Cancer Res 2010;16:2932-2938.
35. Kappes F, Khodadoust MS, Yu L et al. DEK expression in melanocytic lesions. Hum Pathol 2011;42:932-938.
36. Patel RM, Walters LL, Kappes F et al. DEK expression in merkel cell carcinoma and small cell carcinoma. J Cutan Pathol 2012;39:753-757.
37. Liu S, Wang X, Sun F et al. DEK overexpression is correlated with the clinical features of breast cancer. Pathol Int 2012;62:176-181.
38. Liu K, Feng T, Liu J, et al. Silencing of the DEK gene induces apoptosis and senescence in CaSki cervical carcinoma cells via the upregultaion of NF-κB p65. Biosci Res 2012;32:323-332.
39. Kavanaugh GM, Wise-Draper TM, Morreale RJ et al. The human DEK oncogene regulates DNA damage response signaling and repair. Nucleic Acid Res 2011;39:7465-7476.
40. Kim DW, Chae JI, Kim JY et al. Proteomic analysis of apoptosis related proteins regulated by proto-oncogene protein DEK. J Cell Biochem 2009;106:1048-1059.
41. Aravind L, Koonin EV. SAP-a putative DNA-binding motif involved in chromosomal organization. Trends Biochem Sci 2000; 25:112-114.
42. Böhm F, Kappes F, Scholten I et al. The SAP-box domain of chromatin protein DEK. Nucleic Acids Res 2005;33:1101-1110.
43. Devany M, Kappes F, Chen KM et al. Solution NMR structure of the N-terminal domain of the human DEK protein. Protein Sci 2008;17: 205-215.
44. Fu GK, Grosveld G, Markovitz DM. DEK, an autoantigen involved in a chromosomal translocation in acute myelogenous leukemia, binds to the HIV-2 enhancer. Proc Natl Acad Sci U S A 1997;94:1811-1815.
45. Waldmann T, Baack M, Richter N et al. Structure-specific binding of the proto-oncogene protein DEK to DNA. Nucleic Acids Res 2003;31: 7003-7010.
46. Waldmann T, Eckerich C, Baack M et al. The ubiquitous chromatin protein DEK alters the structure of DNA by introducing positive supercoils. J Biol Chem 2002;277:24988-24994.
47. Le Hir H, Gatfield D, Izaurralde E et al. The exon-exon junction complex provides a binding platform for factors involved in mRNA export and nonsense-mediated mRNA decay. EMBO J 2001;20:4987-4997.
48. Le Hir H, Izaurralde E, Maquat LE et al. The spliceosome deposits multiple proteins 20-24 nucleotides upstream of mRNA exon-exon junctions. EMBO J 2000;19:6860-6869.
49. McGarvey T, Rosonina E, McCracken S et al. The acute myeloid leukemia-associated protein, DEK, forms a splicing-dependent interaction with exon-product complexes. J Cell Biol 2000;150:309-320.
50. Soares LM, Zanier K, Mackereth C et al. Intron removal requires proofreading of U2AF/30 splice site recognition by DEK. Science 2006;312:1961-1965.
51. Szer IS, Sierakowska H, Szer W. A novel autoantibody to the putative oncoprotein DEK in pauciarticular onset juvenile rheumatoid arthritis. J Rheumatol 1994;21:2136-2142.
52. Murray KJ, Szer W, Grom AA et al. Antibodies to the 45 kDa DEK nuclear antigen in pauciarticular onset juvenile rheumatoid arthritis and iridocyclitis: selective association with MHC gene. J Rheumatol 1997;24:560-567.
53. Kappes F, Burger K, Baack M et al. Subcellular localization of the human proto-oncogene protein DEK. J Biol Chem 2001;276:26317-26323.
54. Mor-Vaknin N, Punturieri A, Sitwala K et al. The DEK nuclear autoantigen is a secreted chemotactic factor. Mol Cell Biol 2006;26:9484-9496.
55. Ageberg M, Gullberg U, Lindmark A. The involvement of cellular proliferation status in the expression of the human proto-oncogene DEK. Haematologica 2006;91:268-269.
56. Oancea C, Rüster B, Henschler R et al. The t(6;9) associated DEK/CAN fusion protein targets a population of long-term repopulating hematopoietic stem cells for leukemogenic transformation. Leukemia 2010;24:1910-1919.
57. Christopherson KW 2nd, Hangoc G, Mantel CR et al. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 2004;305:1000-1003.
58. Gotoh A, Takahira H, Geahlen RL et al. Cross-linking of integrins induces tyrosine phosphorylation of the proto-oncogene product Vav and the protein tyrosine kinase Syk in human factor-dependent myeloid cells. Cell Growth Differ 1997;8:721-729.
59. Gotoh A, Takahira H, Mantel C et al. Steel factor induces serine phosphorylation of Stat3 in human growth factor-dependent myeloid cell lines. Blood 1996;88:138-145.
60. Hendrie PC, Broxmeyer HE. Myeloid cell proliferation stimulated by steel factor is pertussis toxin sensitive and enhanced by cholera toxin. Int J Immunopharmacol 1994;16:547-560.
61. Hendrie PC, Miyazawa K, Yang YC et al. Mast cell growth factor (c-kit ligand) enhances cytokine stimulation of proliferation of the human factor-dependent cell line, M07e. Exp Hematol 1991;19:1031-1037.
62. Horie M, Broxmeyer HE. Involvement of immediate-early gene expression in the synergistic effects of steel factor in combination with granulocyte- macrophage colony-stimulating factor or interleukin-3 on proliferation of a human factor-dependent cell line. J Biol Chem 1993; 268:968-973.
63. Lee Y, Gotoh A, Kwon HJ et al. Enhancement of intracellular signaling associated with hematopoietic progenitor cell survival in response to SDF-1/CXCL12 in synergy with other cytokines. Blood 2002;99: 4307-4317.
64. Mantel C, Luo Z, Hendrie P et al. Steel factor and granulocytemacrophage colony stimulating factor act together to enhance cholinelipid turnover during synergistically stimulated proliferation of the human factor dependent cell line, M07E. Biochem Biophys Res Commun 1993;197:978-984.
65. Miyazawa K, Hendrie PC, Kim YJ et al. Recombinant human interleukin-9 induces protein tyrosine phosphorylation and synergizes with steel factor to stimulate proliferation of the human factordependent cell line, M07e. Blood 1992;80:1685-1692.
66. Miyazawa K, Hendrie PC, Mantel C et al. Comparative analysis of signaling pathways between mast cell growth factor (c-kit ligand) and granulocyte-macrophage colony-stimulating factor in a human factordependent myeloid cell line involves phosphorylation of Raf-1, GTPase-activating Protein And mitogen-activated protein kinase. Exp Hematol 1991;19:1110-1123.
67. Miyazawa K, Toyama K, Gotoh A et al. Ligand-dependent polyubiquitination of c-kit gene product: a possible mechanism of receptor down modulation in M07e cells. Blood 1994;83:137-145.
68. Ritchie A, Gotoh A, Gaddy J et al. Thrombopoietin upregulates the promoter conformation of p53 in a proliferation-independent manner coincident with a decreased expression of Bax: potential mechanisms for survival enhancing effects. Blood 1997;90:4394-4402.
69. Patel MJ, Liu W, Sykes MC et al. Identification of mechanosensitive genes in osteoblasts by comparative microarray studies using the rotating wall vessel and the random positioning machine. J Cell Biochem 2007;101:587-599.
70. Johnson LA, Clasper S, Holt AP et al. An inflammation-induced mechanism for leukocyte transmigration across lymphatic vessel endothelium. J Exp Med 2006;203:2763-2777.
71. Larson BL, Ylöstalo J, Prockop DJ. Human multipotent stromal cells undergo sharp transition from division to development in culture. Stem Cells 2008;26:193-201.
72. Shibata T, Kokubu A, Miyamato M et al. DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendicrine carcinoma of the lung. Oncogene 2010;29: 4671-81.
73. Sansing HA, Sarkeshik A, Yates JR et al. Integrin ab1, avb, a6b effectors p130Cas, Src and Talin regulate carcinoma invasion and chemoresistance. Biochem Biophys Res Commun 2011;406:171-176.